Protocol Code: D8991C00001 IND number: 174954Protocol Title: A Randomised Open label Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα low Expressing High grade Platinum resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01).
Learn More About This Study
